Global Eosinophilic Esophagitis Drug Market Growth 2023-2029

Global Eosinophilic Esophagitis Drug Market Growth 2023-2029

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.

This report studies the eosinophilic esophagitis drug market.
LPI (LP Information)' newest research report, the “Eosinophilic Esophagitis Drug Industry Forecast” looks at past sales and reviews total world Eosinophilic Esophagitis Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Eosinophilic Esophagitis Drug sales for 2023 through 2029. With Eosinophilic Esophagitis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Eosinophilic Esophagitis Drug industry.
This Insight Report provides a comprehensive analysis of the global Eosinophilic Esophagitis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Eosinophilic Esophagitis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Eosinophilic Esophagitis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Eosinophilic Esophagitis Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Eosinophilic Esophagitis Drug.
The global Eosinophilic Esophagitis Drug market size is projected to grow from US$ 127 million in 2022 to US$ 187.2 million in 2029; it is expected to grow at a CAGR of 187.2 from 2023 to 2029.
AstraZeneca, GSK and Bayer are the leading producers of eosinophilic esophagitis drug, which together account for about 80% of the market.
North America is the leading region, accounting for more than 30% of the market, followed by Europe at nearly 30%.
This report presents a comprehensive overview, market shares, and growth opportunities of Eosinophilic Esophagitis Drug market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Budesonide
Fluticasone
Others
Segmentation by application
Hospitals
Clinics
Drugstore
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
GSK
Bayer
Adare Pharmaceuticals
DBV Technologies
Dr. Falk Pharma
Quorum Innovations
Takeda
Calypso
Celgene
Regeneron
Key Questions Addressed in this Report
What is the 10-year outlook for the global Eosinophilic Esophagitis Drug market?
What factors are driving Eosinophilic Esophagitis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Eosinophilic Esophagitis Drug market opportunities vary by end market size?
How does Eosinophilic Esophagitis Drug break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.